Stress link to Alzheimer's goes under the spotlight

Chronic stress is being investigated in a new Alzheimer's Society funded research project as a risk factor for developing dementia.

It is part of a £1.5 million package of six grants being given by the charity fighting to find a cause, cure and way to prevent the disease.

Clive Holmes, Professor of Biological Psychiatry at the University of Southampton, is lead investigator for the stress study. He says: "All of us go through stressful events. We are looking to understand how these may become a risk factor for the development of Alzheimer's.

"This is the first stage in developing ways in which to intervene with psychological or drug based treatments to fight the disease."

More effective coping methods for dealing with stress and a greater understanding of its biological impact may provide the answer.

The study scheduled to start in in less than a week will involve 18 months monitoring 140 people aged 50 and over with mild cognitive impairment.

The participants will be assessed for levels of stress and assessed for any progression from mild cognitive impairment to .

About 60 per cent of people with mild cognitive impairment are known to go on to develop Alzheimer's.

Professor Holmes adds: "There is a lot of variability in how quickly that progression happens; one factor increasingly implicated in the process is chronic stress. That could be driven by a big change – usually negative – such as a prolonged illness, injury or a major operation.

"We are looking at two aspects of stress relief – physical and psychological – and the body's response to that experience. Something such as bereavement or a traumatic experience – possibly even moving home – is also a potential factor."

Alzheimer's Society research manager, Anne Corbett, says: "The study will look at the role chronic stress plays in the progression from mild thinking and memory problems - Mild Cognitive Impairment - to Alzheimer's disease.

"We feel this is a really important area of research that needs more attention. The results could offer clues to new treatments or better ways of managing the condition.

"It will also be valuable to understand how different ways of coping with stressful life events could influence the risk of developing Alzheimer's disease."

The participants in the trial will be compared to a group of 70 people without memory problems, who will be tested as a 'control group'. All the people taking part will be asked to complete cognitive tests in order to track their cognitive health.

Questionnaires will assess their personality type, style of coping with stressful events and their perceived level of social support and mood.

The process will be repeated after 18 months to measure any conversion from mild cognitive impairment to Alzheimer's disease. Stressful life events will also be recorded.

The researchers will take blood and saliva samples every six months to measure biological markers of stress. Blood samples will measure immune function and the saliva samples will track levels of cortisol, which is released by the body in response to chronic stress.

A number of illnesses are known to develop earlier or are made worse by , including heart disease, diabetes, cancer and multiple sclerosis. Surprisingly little research has been done in people with mild cognitive impairment or Alzheimer's disease in relation to their experience of stress.

add to favorites email to friend print save as pdf

Related Stories

Education protects against pre-Alzheimer's memory loss

Oct 20, 2008

ST. PAUL, Minn. – People with more education and more mentally demanding occupations may have protection against the memory loss that precedes Alzheimer's disease, according to a study published in the October 21, 2008, ...

Alzheimer's disease risks are gender specific

May 01, 2008

The risks of developing Alzheimer’s disease differ between the sexes, with stroke in men, and depression in women, critical factors, suggests research published ahead of print in the Journal of Neurology Neurosurgery an ...

Recommended for you

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

Report finds scale and cost of dementia escalates

Sep 11, 2014

Dementia UK: The Second Edition, prepared by King's College London and the London School of Economics for the Alzheimer's Society, finds that the cost of dementia to the UK has hit £26 billion a year and ...

User comments